Results 41 to 50 of about 6,006,467 (356)
Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach.
Journal of the American Society of Nephrology, 2015 Kidney diseases caused by genetic or acquired dysregulation of the complement alternative pathway (AP) are traditionally classified on the basis of clinical presentation (atypical hemolytic uremic syndrome as thrombotic microangiopathy), biopsy ...
A. D. De Vriese +4 more
semanticscholar +1 more source
Frontiers in Immunology, 2021 Dysregulation of complement activation causes a number of diseases, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Emma Ispasanie +10 more
doaj +1 more source
Plant Biotechnology Journal, 2015 Summary The synthesis and accumulation of omega‐3 long‐chain polyunsaturated fatty acids in transgenic Camelina sativa is demonstrated using the so‐called alternative pathway.
N. Ruíz-López +4 more
semanticscholar +1 more source
An alternative cytokinin biosynthesis pathway [PDF]
Proceedings of the National Academy of Sciences, 2000 Studies of de novo cytokinin biosynthesis in isopentenyltransferase ( ipt )-transformed Arabidopsis thaliana , involving in vivo deuterium labeling and mass spectrometry, showed that the biosynthetic rate of zeatinriboside-5′-monophosphate was
Nam-Hai Chua +7 more
openaire +3 more sources
Tribochemistry as an Alternative Synthesis Pathway [PDF]
Lubricants, 2020 While reactions driven by mechanical force or stress can be labeled mechanochemical, those specifically occurring at a sliding interface inherit the name tribochemical, which stems from the study of friction and wear: tribology. Increased perception of tribochemical reactions has been gained through technological advancement, and the development of new
Hayden Carlton +2 more
openaire +3 more sources
Frontiers in Immunology, 2023 IntroductionSeveral diseases caused by the dysregulation of complement activation can be treated with inhibitors of the complement components C5 and/or C3.
Emma Ispasanie +12 more
doaj +1 more source
FoxO1 signaling in B cell malignancies and its therapeutic targeting
FEBS Letters, EarlyView.FoxO1 has context‐specific tumor suppressor or oncogenic character in myeloid and B cell malignancies. This includes tumor‐promoting properties such as stemness maintenance and DNA damage tolerance in acute leukemias, or regulation of cell proliferation and survival, or migration in mature B cell malignancies.
Krystof Hlavac +3 more
wiley +1 more source
Insights into PI3K/AKT signaling in B cell development and chronic lymphocytic leukemia
FEBS Letters, EarlyView.This Review explores how the phosphoinositide 3‐kinase and protein kinase B pathway shapes B cell development and drives chronic lymphocytic leukemia, a common blood cancer. It examines how signaling levels affect disease progression, addresses treatment challenges, and introduces novel experimental strategies to improve therapies and patient outcomes.
Maike Buchner
wiley +1 more source
The Role of Properdin in Killing of Non-Pathogenic Leptospira biflexa
Frontiers in Immunology, 2020 Properdin (P) is a positive regulatory protein that stabilizes the C3 convertase and C5 convertase of the complement alternative pathway (AP). Several studies have suggested that properdin can bind directly to the surface of certain pathogens regardless ...
Adriana Patricia Granados Martinez +7 more
doaj +1 more source
Frontiers in Immunology, 2022 Activation of the alternative pathway (AP) of complement is thought to play an important role in Immunoglobin A nephropathy (IgAN). Our previous study showed that rs4151657 within the complement factor B (CFB) gene increased the risk of IgAN. The protein
Dian-Chun Shi +18 more
doaj +1 more source